Reuters logo
BRIEF-US FDA approves new once-weekly BYDUREON® BCise™ injectable medicine for patients with Type-2 diabetes
October 23, 2017 / 12:33 PM / in a month

BRIEF-US FDA approves new once-weekly BYDUREON® BCise™ injectable medicine for patients with Type-2 diabetes

Oct 23 (Reuters) - AstraZeneca PLC

* US FDA approves new easy-to-use, once-weekly BYDUREON® BCise™ injectable medicine for patients with Type-2 diabetes

* Astrazeneca PLC - ‍BYDUREON BCise will be available for patients in US in Q1 of 2018​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below